EAP for the Treatment of Glioblastoma With PVSRIPO
This is an open-label, single-arm, non-randomized, intermediate-sized expanded access study
evaluating the safety, efficacy, and tolerability of PVSRIPO delivered via intratumoral
infusion, in subjects with glioblastoma (GBM) who are ineligible to participate in clinical
study with PVSRIPO that is currently open to enrollment.